info@mail.ucallm.com
From Genome Stability Maintenance to Cancer Therapeutic Response — Empowering Comprehensive DNA Repair Profiling with Validated Tumor Suppressor Antibody Solutions
Maintaining genome integrity is a fundamental requirement for normal cellular function and organismal health. The DNA damage response (DDR) network acts as a sophisticated surveillance system that detects genomic lesions, coordinates repair processes, regulates cell cycle progression, and determines cellular outcomes including repair, senescence, apoptosis, or survival adaptation.
Tumor suppressor proteins serve as critical guardians of genome stability by controlling DNA damage checkpoints, replication fidelity, chromosomal integrity, and cellular stress responses. During tumor development, mutations or functional loss of key tumor suppressor pathways disrupt genomic maintenance systems, allowing cancer cells to accumulate genetic alterations, tolerate replication stress, evolve under selective pressure, and acquire resistance to therapeutic intervention.The DNA damage response system integrates multiple interconnected mechanisms, including:
· DNA damage recognition and signaling
· Cell cycle checkpoint activation
· DNA double-strand break repair
· Homologous recombination (HR) repair
· Non-homologous end joining (NHEJ)
· Base excision repair (BER)
· Nucleotide excision repair (NER)
· Mismatch repair (MMR)
· Interstrand crosslink repair pathways
· Tumor suppressor-mediated genome surveillance
Our validated antibody portfolio provides comprehensive tools for dissecting tumor suppressor biology and DNA repair mechanisms, enabling researchers to investigate molecular events from initial DNA damage recognition and checkpoint activation to repair pathway engagement, genomic instability, and therapeutic response.
By integrating high-quality DDR biomarkers with advanced research platforms, including immunohistochemistry (IHC), immunofluorescence (IF), Western blot, flow cytometry, and multiplex spatial analysis, our antibody solutions support detailed characterization of cancer genome maintenance programs and treatment-associated molecular changes.
Tumor Suppressor & DNA Damage Repair Biomarker Antibody Portfolio
——Comprehensive Solutions for Genome Stability Profiling, DNA Repair Pathway Analysis, and Cancer Mechanism Discovery
Comprehensive characterization of DNA damage responses requires integrated analysis of damage sensors, repair enzymes, checkpoint regulators, and tumor suppressor networks.
Our antibody portfolio supports investigation of major DNA repair pathways and cancer-associated genome instability mechanisms.
Research Focus | Representative Biomarkers | Research Applications |
DNA Damage Recognition & Checkpoint Activation | ATM, ATR, Chk1, Chk2, γH2AX, Histone H2A.X | Detection of DNA damage signaling, replication stress, and checkpoint activation |
Tumor Suppressor Pathway Regulation | p53, p21/CDKN1A, p16/CDKN2A, RB | Analysis of growth arrest, apoptosis, senescence, and tumor suppression mechanisms |
Base Excision Repair (BER) | PARP1, APEX1 (APE1), POLB, XRCC1, LIG3 | Investigation of oxidative DNA damage repair and PARP-dependent repair pathways |
Double-Strand Break Repair — NHEJ | RKDC (DNA-PKcs), XRCC6 (Ku70), XRCC5 (Ku80), XRCC4, LIG4 | Characterization of DNA end recognition and classical NHEJ repair activity |
Double-Strand Break Repair — Homologous Recombination (HR) | BRCA1, BRCA2, RAD51, RAD52, RAD54L, XRCC2, XRCC3, RAD51C, RAD51D | Evaluation of HR repair competency and synthetic lethality mechanisms |
MRN DNA Damage Sensor Complex | MRE11, RAD50, NBS1 | Analysis of early double-strand break recognition and ATM pathway activation |
Nucleotide Excision Repair (NER) | ERCC1, XPA, XPC, ERCC2 (XPD), ERCC4 (XPF), ERCC5 (XPG) | Investigation of bulky DNA adduct repair and chemotherapy resistance |
Mismatch Repair (MMR) | MLH1, MSH2, MSH6, PMS2 | Microsatellite instability (MSI) analysis and cancer classification |
Fanconi Anemia Crosslink Repair | FANCA, FANCD2, FANCI, FANCL, FANCM | Study of DNA interstrand crosslink repair and platinum drug sensitivity |
Telomere Protection & Genome Stability | TRF1, TRF2,TERT, DKC1, POT1, TINF2, ACD , TERF2IP | Investigation of cellular immortalization and chromosome-end maintenance |
Core Tumor Suppressor & DNA Repair Targets
——Molecular Function, Biological Significance, and Cancer Research Applications
Target | Biological Function | Research Significance |
p53 | Master tumor suppressor activated by DNA damage and cellular stress; regulates apoptosis, senescence, and checkpoint responses | Central biomarker for tumor suppressor pathway status and cancer progression |
p21 (CDKN1A) | Cyclin-dependent kinase inhibitor induced by p53 activation | Marker of cell cycle arrest, senescence, and DNA damage response |
p16 (CDKN2A) | CDK4/6 inhibitor controlling RB pathway activation | Indicator of tumor suppression and cellular senescence |
RB Protein | Controls G1/S transition by suppressing E2F transcription factors | Loss of RB function promotes uncontrolled proliferation |
ATM | DNA double-strand break sensor kinase activating checkpoint signaling | Key marker for radiation response and DNA damage activation |
ATR | Detects replication stress and stalled replication forks | Critical regulator of replication stress tolerance |
Chk1/Chk2 | Downstream checkpoint kinases regulating DNA repair and cell cycle arrest | Biomarkers for checkpoint activation and therapeutic response |
γH2AX | Phosphorylated histone variant accumulating at DNA double-strand breaks | Gold-standard marker for DNA damage detection |
PARP1 | DNA single-strand break repair enzyme involved in BER pathway | Essential target for PARP inhibitor studies and synthetic lethality research |
BRCA1 | HR repair regulator controlling DNA end processing and checkpoint activation | Biomarker for HR deficiency and PARP inhibitor sensitivity |
BRCA2 | Facilitates RAD51 loading during homologous recombination | Key marker of hereditary cancer and HR pathway status |
RAD51 | Recombinase forming HR repair foci at DNA damage sites | Widely used functional marker for HR activity |
DNA-PKcs | Catalytic component of classical NHEJ repair machinery | Indicator of DSB repair pathway activation |
Ku70/Ku80 | DNA end-binding complex initiating NHEJ repair | Essential markers for DNA break recognition |
MRE11/RAD50/NBS1 | MRN complex responsible for DSB sensing and ATM activation | Early DNA damage response biomarkers |
ERCC1 | Nucleotide excision repair protein involved in DNA adduct removal | Biomarker associated with platinum chemotherapy response |
MLH1 | Core mismatch repair protein maintaining replication fidelity | MSI detection and tumor molecular classification |
FANCA | Fanconi pathway regulator repairing DNA interstrand crosslinks | Marker for DNA crosslink repair capacity |
Featured DNA Damage Repair Research Panels
——Comprehensive Antibody Panels for Genome Stability Profiling, DNA Repair Mechanisms, and Cancer Therapeutic Discovery
DNA repair pathways are highly interconnected networks involving damage recognition, checkpoint activation, repair pathway choice, and cellular fate regulation. Our curated antibody panels enable systematic investigation of DNA repair defects and treatment responses.
n DNA Damage Response & Checkpoint Activation Panel—Profiling DNA Damage Recognition, Signaling Activation, and Repair Initiation
Key Markers
γH2AX | ATM/p-ATM | ATR | Chk1 | Chk2 | p53 |
n Homologous Recombination Repair Panel—valuating HR Deficiency, DNA Repair Capacity, and Synthetic Lethality Mechanisms
Key Markers
BRCA1 | BRCA2 | RAD51 | RAD52 | RAD54 | XRCC2 | XRCC3 | RAD51C |
n Classical NHEJ Repair Panel—Characterizing Double-Strand Break Repair Through End Joining
Key Markers
DNA-PKcs | Ku70 | Ku80 | XRCC4 | Ligase IV |
n Tumor Suppression & Genome Stability Panel—Analyzing Cell Fate Decisions Following DNA Damage
Key Markers
p53 | p21 | p16 | RB | ATM | γH2AX |
Why Researchers Choose Our Tumor Suppressor & DNA Repair Antibody Solutions
Validated Genome Stability Targets. Comprehensive DDR Coverage. Reliable Cancer Research Outcomes.
Our antibody portfolio supports complete DNA damage research workflows:
Research Challenge | Our Solution |
How can I detect DNA damage activation? | γH2AX, ATM, ATR, Chk1/Chk2 marker panels |
How can I study tumor suppressor pathways? | p53, p21, p16, RB antibodies |
How can I analyze HR deficiency? | BRCA1, BRCA2, RAD51 repair panels |
How can I investigate DSB repair mechanisms? | DNA-PKcs, Ku70/80, XRCC4, Ligase IV antibodies |
How can I evaluate therapy resistance? | PARP1, ERCC1, DDR pathway biomarkers |
How can I improve reproducibility? | Validated antibodies optimized for WB, IF, IHC, FC, and multiplex applications |
Key reference
1. Madhusudan S, Hickson ID. DNA repair inhibition: a selective tumour targeting strategy. Trends in Molecular Medicine. 2005;11(11):503-511.
2. Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39-85.
3. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366-374.
4. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296-307.
5. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005;4(5):421-440.
6. Bassing CH, Alt FW. The cellular response to general and programmed DNA double strand breaks. DNA Repair. 2004;3(8):781-796.
7. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913-917.
8. Farmer H, McCabe H, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-921.
9. Middleton MR, Margison GP. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol. 2003;4(1):37-44.